Vimian Group AB, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Adela Dashian from Jefferies maintained a Hold rating on the stock and has a SEK37.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adela Dashian’s rating is based on several factors that reflect the current performance and future potential of Vimian Group AB. The company’s third-quarter results exceeded expectations, with a notable 19% year-over-year increase in net revenue, reaching EUR 104.3 million. This growth was primarily driven by strong performances in the Specialty Pharma and Veterinary Services segments, both achieving 11% organic growth. Additionally, the MedTech segment returned to organic growth with a 5% increase, despite challenges in the US surgery market.
Despite these positive results, the Hold rating suggests a cautious approach, as the company’s adjusted EBITA margin slightly declined by 0.5 percentage points year-over-year to 24.5%. While the quarterly performance and MedTech’s recovery are likely to boost investor confidence, the Hold rating indicates that the stock’s current price may already reflect these improvements, and further upside might be limited in the near term. Therefore, investors are advised to maintain their positions and monitor the company’s progress closely.
According to TipRanks, Dashian is a 3-star analyst with an average return of 2.4% and a 38.55% success rate. Dashian covers the Industrials sector, focusing on stocks such as Tomra Systems ASA, Munters Group AB, and Systemair AB.